After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼(lenvatinib,一种多靶点受体酪氨酸激酶抑制剂)治疗在多种肿瘤中均显示出临床疗效,但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...
在面对癌症时,免疫疗法的不断进步给患者带来了希望。然而,出乎意料的是,许多患者在接受抗PD-1疗法时依旧难逃耐药的困扰。是什么原因导致了这种现象?为何部分患者会在免疫治疗中失去应有的效果?这些问题也许在最近浙江大学医学院第二附属医院发表在《Cell Reports Medicine》期刊的研究成果中找到了答案。
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...
AEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding ...
IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the "brake” ...
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...
浙江大学医学院蔡志坚教授联合浙江农林大学冯华军教授等,在 Cell 子刊 Cell Reports Medicine 上发表了题为: MFGE8 induces anti-PD-1 therapy resistance by promoting ...
Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...
"Aethlon Medical treats first subject with Hemopurifier device in Australia" was originally created and published by Medical ...
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...